News

The selected solutions include Oracle Siebel Clinical Trial Management System and Oracle Health Sciences Clinical Development Analytics. Oracle Siebel Clinical Trial Management System allows global clinical organizations to

The company seeks to introduce new patent-pending tiopronin and potassium citrate delayed release (DR) compounded formulations, which are expected to be available in April this year. The new

Mylan will pay SEK165 per share, bringing the total value of the deal to $9.9bn including Meda’s debt. The transaction is anticipated to close by the end of

The hold comes as a result of the deaths that have occurred during the experimental trial. Patients have reportedly died of cardiac arrest and bleeding inside the skull.

In its draft guidance, the National Institute of Health and Care Excellence said that the benefits of Praluent are uncertain. The draft guidance has not recommended alirocumab, alone

The pay-for-performance agreements are expected to set pricing on certain drugs based on how they work for certain patients. In July 2015, the US Food and Drug Administration

The company said that it was informed by FDA that it will require another three months to complete its New Drug Application (NDA) review for eteplirsen. Sarepta received

Pharming entered into the original exclusive distribution agreement with Cytobioteck in May 2015 for the distribution of RUCONEST(R) in Colombia and Venezuela. Under the extended agreement, Cytobioteck will

One of these medicines, fulvestrant (Faslodex) for advanced breast cancer, was accepted following consideration under the SMC’s Patient and Clinician Engagement Process (PACE), which aims to improve patient